Semaglutide

Semaglutide is the drug that transformed weight loss from a willpower narrative into an endocrinology conversation. Before semaglutide, the pharmaceutical approach to obesity was a graveyard of withdrawn drugs (fenfluramine, sibutramine) and marginally effective ones. Semaglutide changed the calculus entirely: a 15% average body weight reduction in clinical trials, cardiovascular mortality benefits, and a mechanism rooted in correcting the same hormonal pathways that regulate appetite in lean individuals.

Developed by Novo Nordisk, semaglutide is a GLP-1 receptor agonist — a synthetic version of the naturally occurring incretin hormone glucagon-like peptide-1. It is marketed under three brand names for different indications: Ozempic (type 2 diabetes, injectable), Wegovy (chronic weight management, injectable), and Rybelsus (type 2 diabetes, oral tablet). It is also the most widely compounded peptide in the United States, with a sprawling market of compounding pharmacies producing generic versions at a fraction of brand-name cost.

TriedRx maintains independent testing data on 84 vendors and 920 samples of semaglutide — covering both compounded and research-grade products. This profile covers everything a consumer or clinician needs to know about the molecule.

How Semaglutide Works

Semaglutide is a 31-amino-acid peptide analogue of human GLP-1, sharing 94% structural homology with the native hormone. The critical modification is a C-18 fatty diacid chain attached at lysine-26, which enables non-covalent binding to serum albumin. This albumin binding accomplishes two things: it shields semaglutide from DPP-4 enzymatic degradation (which destroys native GLP-1 within two minutes), and it creates a circulating reservoir that extends the effective half-life to approximately 7 days.

[CITATION: PubMed study needed on semaglutide molecular structure, albumin binding, and pharmacokinetic profile]

The result is a once-weekly injection that maintains steady-state GLP-1 receptor activation, as opposed to the brief, pulsatile signaling that native GLP-1 provides. This sustained activation produces more potent effects across all GLP-1-mediated pathways.

Mechanism of Action

Semaglutide's therapeutic effects flow from GLP-1 receptor activation in multiple tissues:

Appetite and food intake: GLP-1 receptors in the hypothalamus (arcuate nucleus, paraventricular nucleus) and brainstem (nucleus tractus solitarius, area postrema) mediate semaglutide's appetite-suppressive effects. Functional MRI studies in humans have shown that semaglutide reduces activation in brain regions associated with food reward and craving, while increasing activation in regions associated with satiety and cognitive control of eating.

[CITATION: PubMed study needed on semaglutide fMRI brain imaging studies showing altered food reward processing]

Gastric emptying: Semaglutide slows the rate at which the stomach empties its contents into the duodenum. This prolongs the feeling of fullness after eating and contributes to reduced caloric intake. The gastric emptying delay is most pronounced during the first few weeks of treatment and partially attenuates over time, which correlates with the reduction in nausea that most patients experience.

Pancreatic function: Semaglutide enhances glucose-dependent insulin secretion from beta cells and suppresses inappropriate glucagon secretion from alpha cells. Both effects are glucose-dependent — meaning they activate primarily when blood glucose is elevated, which limits the risk of hypoglycemia when semaglutide is used as monotherapy.

Cardiovascular effects: The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) with semaglutide 2.4mg in patients with established cardiovascular disease and overweight/obesity but without diabetes. The mechanisms underlying this benefit are not fully elucidated but may include direct anti-inflammatory effects, reduction in atherosclerotic plaque vulnerability, and improvements in cardiometabolic risk factors.

[CITATION: PubMed study needed on SELECT cardiovascular outcomes trial — Lincoff et al., NEJM 2023]

For a broader overview of GLP-1 biology, see our GLP-1 Peptide Category Guide.

Clinical Trial Data: The STEP Program

Semaglutide's weight-management evidence base comes primarily from the STEP (Semaglutide Treatment Effect in People with obesity) trial program, one of the most comprehensive obesity drug development programs ever conducted.

STEP 1: The Landmark Trial

• Population: 1,961 adults with BMI >= 30 (or >= 27 with at least one comorbidity), without type 2 diabetes
• Design: Randomized, double-blind, placebo-controlled
• Duration: 68 weeks
• Results: Semaglutide 2.4mg produced -14.9% average body weight loss vs. -2.4% with placebo. 32.0% of semaglutide-treated participants achieved >= 20% weight loss.

[CITATION: PubMed study needed on STEP 1 trial full results — Wilding et al., NEJM 2021]

STEP 2: Obesity With Type 2 Diabetes

• Population: 1,210 adults with type 2 diabetes and BMI >= 27
• Results: Semaglutide 2.4mg produced -9.6% weight loss vs. -3.4% with placebo. HbA1c decreased by -1.6 percentage points. Weight loss was lower than in STEP 1, consistent with the observation that patients with type 2 diabetes tend to lose less weight on GLP-1 agonists than those without diabetes.

[CITATION: PubMed study needed on STEP 2 trial results]

STEP 3: Intensive Behavioral Therapy

• Population: 611 adults with obesity
• Results: Semaglutide 2.4mg combined with intensive behavioral therapy (30 counseling sessions) produced -16.0% weight loss over 68 weeks, suggesting a modest additive effect of behavioral intervention on top of pharmacotherapy.

STEP 4: Withdrawal Design

• Population: 902 adults who all received semaglutide 2.4mg for 20 weeks, then were randomized to continue semaglutide or switch to placebo
• Results: Participants who continued semaglutide achieved -17.4% total weight loss at 68 weeks. Those switched to placebo regained weight, ending at -5.0% from baseline. This trial established that semaglutide's weight-loss effect requires continued treatment — discontinuation leads to substantial regain.

[CITATION: PubMed study needed on STEP 4 withdrawal trial results — Rubino et al., JAMA 2021]

STEP 5: Two-Year Data

• Population: 304 adults followed for 104 weeks
• Results: Semaglutide 2.4mg produced -15.2% weight loss over 2 years, demonstrating durability of effect with continued treatment.

SELECT: Cardiovascular Outcomes

• Population: 17,604 adults with established cardiovascular disease, BMI >= 27, and no diabetes
• Duration: Median follow-up 39.8 months
• Results: 20% reduction in MACE (composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke). This was the first trial to demonstrate that a weight-loss drug reduces cardiovascular events, earning semaglutide the only cardiovascular risk reduction indication among GLP-1 agonists used for weight management.

[CITATION: PubMed study needed on SELECT trial cardiovascular outcomes — Lincoff et al., NEJM 2023]

Ozempic vs. Wegovy vs. Rybelsus

Semaglutide is sold under three brand names, each serving a distinct indication and patient population:

Key distinctions:

Ozempic was the first semaglutide product approved, for type 2 diabetes. Its maximum dose is 2mg, lower than Wegovy's 2.4mg. Despite not having an obesity indication, Ozempic is widely prescribed off-label for weight management — a practice that has contributed to supply shortages.

Wegovy is the dedicated weight-management formulation, with the higher 2.4mg maximum dose. It also carries the cardiovascular risk reduction indication based on the SELECT trial — a claim that Ozempic does not have.

Rybelsus is the oral formulation, using the absorption enhancer SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) to enable intestinal absorption of the peptide. It must be taken on an empty stomach with no more than 4 ounces of water, and patients must wait at least 30 minutes before eating, drinking, or taking other oral medications. Its bioavailability is approximately 0.4-1% — far lower than injectable semaglutide — which is why the oral doses (3-14mg) are much higher than injectable doses (0.25-2.4mg) on an absolute basis.

[CITATION: PubMed study needed on oral semaglutide SNAC absorption enhancer pharmacokinetics]

Dosing Protocol

Injectable Semaglutide (Ozempic/Wegovy)

The dose-titration schedule for Wegovy (weight management):

• Weeks 1-4: 0.25mg once weekly
• Weeks 5-8: 0.5mg once weekly
• Weeks 9-12: 1.0mg once weekly
• Weeks 13-16: 1.7mg once weekly
• Week 17+: 2.4mg once weekly (maintenance dose)

Research has examined this 16-week escalation schedule extensively. Accelerating the titration increases gastrointestinal side effects without improving long-term outcomes. Some clinicians extend the escalation period for patients with significant nausea, spending 8 weeks at each dose level rather than 4.

Injection sites: Abdomen, thigh, or upper arm. Subcutaneous injection. Rotate sites to prevent lipodystrophy.

Oral Semaglutide (Rybelsus)

• Month 1: 3mg once daily (initiation dose)
• Month 2: 7mg once daily
• Month 3+: 14mg once daily (maintenance dose)

Must be taken on an empty stomach with no more than 4 oz (120 mL) of plain water, at least 30 minutes before the first food, drink, or other oral medication of the day.

Side Effects and Safety

Common Side Effects

[CITATION: PubMed study needed on semaglutide 2.4mg adverse event rates from STEP 1 safety data]

The GI side effects are the dominant tolerability concern. They are most severe during dose escalation and typically improve over weeks to months at a stable dose. Approximately 7% of participants in STEP 1 discontinued semaglutide due to adverse events.

Serious Safety Concerns

Pancreatitis: Acute pancreatitis has been reported. Semaglutide should be discontinued if pancreatitis is suspected and not restarted if confirmed. Patients with a history of pancreatitis should generally avoid GLP-1 agonists.

Gallbladder events: Cholelithiasis and cholecystitis rates were elevated with semaglutide vs. placebo, consistent with the association between rapid weight loss and gallstone formation.

Thyroid C-cell tumors: Boxed warning based on rodent carcinogenicity studies. Contraindicated in patients with personal or family history of MTC or MEN2. Human data has not confirmed this risk.

Diabetic retinopathy complications: In SUSTAIN-6 (the diabetes cardiovascular outcomes trial), semaglutide was associated with a higher rate of diabetic retinopathy complications, likely related to rapid improvement in glycemic control rather than a direct drug effect.

Suicidal ideation: Investigated by the EMA and FDA. Current evidence does not support a causal association, but monitoring continues.

Gastroparesis: Rare reports of persistent gastroparesis following GLP-1 agonist use. The true incidence and causality remain under investigation.

[CITATION: PubMed study needed on semaglutide serious adverse events — comprehensive safety review]

For more on the facial effects of GLP-1-mediated weight loss, see our guide on Ozempic face.

The Compounded Semaglutide Market

The compounded semaglutide market has exploded since 2022, driven by three factors: the high cost of brand-name products ($1,000-1,600/month without insurance), persistent supply shortages, and regulatory provisions that permit compounding of shortage drugs.

How It Works

Under FDA Section 503A, individual compounding pharmacies can compound copies of FDA-approved drugs on the Drug Shortage List in response to individual patient prescriptions. Under Section 503B, outsourcing facilities can compound in larger batches without individual prescriptions. Both pathways have been used for semaglutide.

Compounded semaglutide is typically sold as:

• Lyophilized (freeze-dried) powder requiring reconstitution with bacteriostatic water
• Pre-mixed injectable solutions
• Sublingual formulations (limited data on bioavailability)

Prices range from approximately $100-400/month, depending on the vendor, concentration, and quantity.

Quality Concerns

This is where TriedRx's independent testing becomes critical. Our analysis of 920 semaglutide samples from 84 vendors reveals significant quality variation:

• Purity: Ranges from below 90% to above 99% across vendors. Lower-purity products contain degradation products, aggregates, and potential contaminants.
• Potency: Some products contain significantly less semaglutide than labeled, meaning patients receive lower-than-intended doses.
• Sterility: Endotoxin levels and particulate matter vary. Products from 503B outsourcing facilities generally show better sterility profiles than those from 503A pharmacies.

Browse our complete vendor testing database and purity analysis reports for detailed results.

Legal Landscape

The legality of compounded semaglutide is contingent on semaglutide's presence on the FDA Drug Shortage List. The FDA has periodically added and removed semaglutide from this list as supply conditions change. When semaglutide is removed from the shortage list, compounding pharmacies face legal jeopardy in continuing to produce it. Novo Nordisk has actively pursued legal action against compounders.

As of April 2026, the regulatory environment remains dynamic. Consumers should verify current shortage list status before purchasing compounded semaglutide.

Drug Interactions

Semaglutide interacts with other medications primarily through gastric emptying delay:

• Oral medications with narrow therapeutic windows: Warfarin, levothyroxine, and oral contraceptives may have altered absorption kinetics. Monitor INR for warfarin, TSH for levothyroxine, and consider backup contraception.
• Insulin and sulfonylureas: Risk of hypoglycemia increases with combination use. Dose reduction of insulin or sulfonylurea is typically necessary.
• Oral semaglutide (Rybelsus) specifically: The SNAC absorption enhancer can interact with other medications taken simultaneously. The 30-minute fasting window is mandatory.

[CITATION: PubMed study needed on semaglutide drug-drug interaction pharmacokinetic studies]

Who Should Consider Semaglutide

Semaglutide may be appropriate for:

• Adults with BMI >= 30, or >= 27 with at least one weight-related comorbidity
• Adults with type 2 diabetes, particularly those who also need weight reduction
• Patients with established cardiovascular disease and overweight/obesity who could benefit from MACE risk reduction
• Patients who prefer weekly injections over daily (compared to liraglutide) or who want an oral option (Rybelsus)
• Patients seeking the most extensively studied GLP-1 agonist with the longest safety track record in the weight-management dose range

Who Should Avoid Semaglutide

• Personal or family history of medullary thyroid carcinoma or MEN2
• History of pancreatitis
• Pregnant or planning pregnancy (discontinue at least 2 months before planned conception due to the long half-life)
• Severe gastroparesis
• Type 1 diabetes
• Active or recent diabetic retinopathy complications (relative contraindication — discuss with ophthalmologist)

For comparison with the next-generation dual agonist, see What Is Tirzepatide?. For pipeline agents that may eventually supplant semaglutide, see Retatrutide, Orforglipron, and CagriSema.